Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:HGSI

Human Genome Sciences (HGSI) Stock Price, News & Analysis

Human Genome Sciences logo

About Human Genome Sciences Stock (NASDAQ:HGSI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company's internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.

Receive HGSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Human Genome Sciences and its competitors with MarketBeat's FREE daily newsletter.

HGSI Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

HGSI Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Human Genome Sciences investors own include Gulf Coast Ultra Deep Royalty Trust (GULTU), Bank of America (BAC), CEMEX (CX), Cisco Systems (CSCO), Citigroup (C), Beazer Homes USA (BZH) and BlackBerry (BB).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:HGSI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:HGSI) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners